Adlai Nortye Ltd
N2U0
Company Profile
Business description
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Contact
685 US Highway 1
New Jersey Biotechnology Development Center, 2nd floor
North BrunswickNJ08902
USAT: +1 848 230-7430
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
123
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.90 | 26.70 | -0.30% |
| CAC 40 | 7,790.27 | 14.40 | -0.18% |
| DAX 40 | 24,323.58 | 47.10 | 0.19% |
| Dow JONES (US) | 42,319.74 | 108.00 | -0.25% |
| FTSE 100 | 8,810.47 | 0.57 | -0.01% |
| HKSE | 23,860.80 | 46.17 | -0.19% |
| NASDAQ | 19,298.45 | 162.04 | -0.83% |
| Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
| NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
| S&P 500 | 5,939.30 | 31.51 | -0.53% |
| S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
| SSE Composite Index | 3,385.69 | 1.59 | 0.05% |